Initiative for Medicines, Access, and Knowledge

From Wikipedia, the free encyclopedia
Initiative for Medicines, Access, and Knowledge
I-MAK logo.jpg
AbbreviationI-MAK
HeadquartersNew York City
Executive Directors
Priti Krishtel and Tahir Amin
Websitehttps://www.i-mak.org/

The Initiative for Medicines, Access, and Knowledge, stylized as I-MAK, is a New York City based 501(c)3 organisation that advocates and litigates for affordable access to medicines.[1]

Organization[]

I-MAK is run by lawyers and doctors,[2] and campaigns for affordably priced medications and challenges what it perceives to be abuse of patent law by large pharmaceutical corporations.[3]

I-MAK was founded by lawyers Priti Krishtel and Tahir Amin and is funded by Open Society Foundations.[1][4]

Activities[]

By 2019, I-MAK had worked on patent law for 33 treatments to 16 different diseases, including cancer, HIV, and diabetes.[5]

I-MAK have launched fourteen legal challenges to Hepatitis C patent filing in China, India, USA, and Ukraine[6] including a successful legal challenge against Gilead Science's patent application in India for Sovaldi.[1][7] In 20018, I-MAK joined three pharmaceutical companies to launch a successful legal challenge to Abbott Laboratories's patent application for its revised version of HIV drug Lopinavir/ritonavir, branded as Kaletra.[2][8]

I-MAK have worked with the government of China to reject parts of pharmaceutical patent applications for HIV medications which were unmerited.[3][9]

References[]

  1. ^ a b c Waltz, Emily (2014-01-01). "Sequenom falls after judge invalidates Down's patent" (PDF). Nature Biotechnology. 32 (1): 5. doi:10.1038/nbt0114-5. ISSN 1546-1696. S2CID 28736102.
  2. ^ a b Chilton, Adam (2011-06-22). "India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent". Journal of Law, Medicine & Ethics. 39 (2): 296–301.
  3. ^ a b Graham, Camilla S. (2020-07-21). "The Current Status of US and Global Access to Direct‐Acting Antiviral Regimens for Hepatitis C Virus Infection". Clinical Liver Disease. 16 (1): 16–19. doi:10.1002/cld.925. ISSN 2046-2484. PMC 7373775. PMID 32714518.
  4. ^ Quigley, Fran (17 November 2017). "Patent Fighters: Taking on Big Pharma". Health and Human Rights Journal.
  5. ^ Te, Nhu. "2019 Unsung Heroes". NonProfit PRO. Retrieved 2022-01-09.
  6. ^ Grillon, Céline; Krishtel, Priti R.; Mellouk, Othoman; Basenko, Anton; Freeman, James; Mendão, Luís; Andrieux-Meyer, Isabelle; Morin, Sébastien (2018). "Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind". Journal of the International AIDS Society. 21 (S2): e25060. doi:10.1002/jia2.25060. ISSN 1758-2652. PMC 5978639. PMID 29633580.
  7. ^ Cohen, Jon (2013-12-13). "Advocates Protest the Cost of a Hepatitis C Cure". Science. 342 (6164): 1302–1303. Bibcode:2013Sci...342.1302C. doi:10.1126/science.342.6164.1302. PMID 24337268.
  8. ^ Harrison, Charlotte (2011-02-01). "Patent watch". Nature Reviews Drug Discovery. 10 (2): 88–89. doi:10.1038/nrd3371. ISSN 1474-1784. PMID 21283096. S2CID 10765469.
  9. ^ Pierson, Brendan (2015-06-19). "China rejects Gilead hepatitis C drug patent -advocacy group". Reuters. Retrieved 2022-01-09.

External links[]

Retrieved from ""